MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant

MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant

BURLINGTON, Mass.--(BUSINESS WIRE)--Jun 18, 2025-

Neoclease Wins Merck’s 2025 Biotech Grant for AI-Powered Gene Therapies Targeting Parkinson’s and Genetic Disorders

Neoclease Wins Merck’s 2025 Biotech Grant for AI-Powered Gene Therapies Targeting Parkinson’s and Genetic Disorders (IN BRIEF) Merck has awarded its 2025 North American Advance Biotech Grant to Neoclease, a Boston-based startup developing AI-designed gene-editing therapies for Parkinson’s disease and other monogenic disorders. Neoclease will benefit from Merck’s technologies, contract testing, regulatory guidance, and hands-on training through i…